company background image
MERK

Merck IDX:MERK Stock Report

Last Price

Rp3.73k

Market Cap

Rp1.7t

7D

-2.6%

1Y

16.2%

Updated

18 May, 2022

Data

Company Financials
MERK fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends3/6

MERK Stock Overview

PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia.

Merck Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Merck
Historical stock prices
Current Share PriceRp3,730.00
52 Week HighRp4,100.00
52 Week LowRp3,090.00
Beta0.92
1 Month Change-0.27%
3 Month Change-7.90%
1 Year Change16.20%
3 Year Change-7.21%
5 Year Change-59.89%
Change since IPO1,244.15%

Recent News & Updates

Shareholder Returns

MERKID PharmaceuticalsID Market
7D-2.6%0.5%-1.9%
1Y16.2%0.5%15.6%

Return vs Industry: MERK exceeded the ID Pharmaceuticals industry which returned 0.5% over the past year.

Return vs Market: MERK matched the ID Market which returned 15.6% over the past year.

Price Volatility

Is MERK's price volatile compared to industry and market?
MERK volatility
MERK Average Weekly Movement2.5%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement6.3%
10% most volatile stocks in ID Market12.0%
10% least volatile stocks in ID Market3.0%

Stable Share Price: MERK is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: MERK's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1970385Evie Yulinhttps://www.merckgroup.com/id-id

PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia. It operates through three segments: Biopharma, Consumer Health, and Others. The company operates in the healthcare, life science, and performance materials sectors.

Merck Fundamentals Summary

How do Merck's earnings and revenue compare to its market cap?
MERK fundamental statistics
Market CapRp1.67t
Earnings (TTM)Rp131.66b
Revenue (TTM)Rp1.06t

12.7x

P/E Ratio

1.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MERK income statement (TTM)
RevenueRp1.06t
Cost of RevenueRp665.71b
Gross ProfitRp398.68b
Other ExpensesRp267.02b
EarningsRp131.66b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)293.89
Gross Margin37.46%
Net Profit Margin12.37%
Debt/Equity Ratio0%

How did MERK perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

42%

Payout Ratio

Valuation

Is Merck undervalued compared to its fair value and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: MERK (IDR3730) is trading below our estimate of fair value (IDR24475.66)

Significantly Below Fair Value: MERK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MERK is good value based on its PE Ratio (12.7x) compared to the ID Pharmaceuticals industry average (20.9x).

PE vs Market: MERK is good value based on its PE Ratio (12.7x) compared to the ID market (18.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MERK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MERK's PB Ratio (2.4x) is in line with the ID Pharmaceuticals industry average.


Future Growth

How is Merck forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Merck has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Merck performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


4.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MERK has high quality earnings.

Growing Profit Margin: MERK's current net profit margins (12.4%) are higher than last year (11%).


Past Earnings Growth Analysis

Earnings Trend: MERK's earnings have grown by 4.2% per year over the past 5 years.

Accelerating Growth: MERK's earnings growth over the past year (83.1%) exceeds its 5-year average (4.2% per year).

Earnings vs Industry: MERK earnings growth over the past year (83.1%) exceeded the Pharmaceuticals industry 12.8%.


Return on Equity

High ROE: MERK's Return on Equity (19.2%) is considered low.


Financial Health

How is Merck's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MERK's short term assets (IDR768.1B) exceed its short term liabilities (IDR282.9B).

Long Term Liabilities: MERK's short term assets (IDR768.1B) exceed its long term liabilities (IDR59.3B).


Debt to Equity History and Analysis

Debt Level: MERK is debt free.

Reducing Debt: MERK had no debt 5 years ago.

Debt Coverage: MERK has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MERK has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Merck current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


3.27%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: MERK's dividend (3.27%) is higher than the bottom 25% of dividend payers in the ID market (1.12%).

High Dividend: MERK's dividend (3.27%) is low compared to the top 25% of dividend payers in the ID market (4.17%).


Stability and Growth of Payments

Stable Dividend: MERK's dividend payments have been volatile in the past 10 years.

Growing Dividend: MERK's dividend payments have fallen over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (41.5%), MERK's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (43.1%), MERK's dividend payments are well covered by cash flows.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average management tenure


CEO

Evie Yulin (54 yo)

2.33yrs

Tenure

Ms. Evie Yulin serves as President Director at PT Merck Tbk since January 2020. She served as a Business Unit Director of PT Astra Zeneca Indonesia and Marketing Director of PT Aventis Pharma (Sanofi Avent...


Leadership Team

Experienced Management: MERK's management team is seasoned and experienced (5.7 years average tenure).


Board Members

Experienced Board: MERK's board of directors are seasoned and experienced ( 11.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Merck Tbk's employee growth, exchange listings and data sources


Key Information

  • Name: PT Merck Tbk
  • Ticker: MERK
  • Exchange: IDX
  • Founded: 1970
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: Rp1.671t
  • Shares outstanding: 448.00m
  • Website: https://www.merckgroup.com/id-id

Number of Employees


Location

  • PT Merck Tbk
  • Jl. TB Simatupang No. 8
  • Pasar Rebo
  • Jakarta Timur
  • Jakarta Raya
  • 13760
  • Indonesia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/18 00:00
End of Day Share Price2022/05/18 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.